Takeda Pharmaceutical (TAK) Non-Current Debt: 2018-2025

  • Takeda Pharmaceutical's Non-Current Debt fell 13.93% to $26.0 billion in Q1 2025 from the same period last year, while for Mar 2025 it was $26.0 billion, marking a year-over-year decrease of 13.93%. This contributed to the annual value of $26.0 billion for FY2025, which is 16.12% down from last year.
  • Takeda Pharmaceutical's Non-Current Debt amounted to $26.0 billion in Q1 2025, which was down 13.93% from $30.2 billion recorded in Q1 2024.
  • Takeda Pharmaceutical's Non-Current Debt's 5-year high stood at $43.6 billion during Q1 2021, with a 5-year trough of $26.0 billion in Q1 2025.
  • Over the past 3 years, Takeda Pharmaceutical's median Non-Current Debt value was $30.2 billion (recorded in 2024), while the average stood at $28.9 billion.
  • Its Non-Current Debt has fluctuated over the past 5 years, first grew by 5.30% in 2021, then decreased by 18.23% in 2022.
  • Takeda Pharmaceutical's Non-Current Debt (Quarterly) stood at $43.6 billion in 2021, then decreased by 18.23% to $35.6 billion in 2022, then decreased by 14.24% to $30.6 billion in 2023, then dropped by 1.17% to $30.2 billion in 2024, then declined by 13.93% to $26.0 billion in 2025.
  • Its last three reported values are $26.0 billion in Q1 2025, $30.2 billion for Q1 2024, and $30.6 billion during Q1 2023.